Dr. Goy Discusses Long-Term Follow-Up Results for Ibrutinib in MCL
December 14th 2017Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, Hackensack Medical Center, discusses long-term follow-up results for ibrutinib (Imbruvica) in relapsed/refractory mantle cell lymphoma.
Watch
Results for the Combination of Selinexor and Daratumumab in Multiple Myeloma
December 14th 2017Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Watch
Phase III Results for Rucaparib in Ovarian Cancer
December 14th 2017Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.
Watch
The Safety and Efficacy of Venetoclax/Obinutuzumab Combo in CLL
December 13th 2017Ian Flinn, MD, Director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the safety, efficacy, and MRD negativity of a combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in patients with previously untreated chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br />
Watch
5-Year Follow-Up of CALGB 40502 Study in TNBC
December 13th 2017Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).
Watch
Follow-Up Results for Ruxolitinib in the Second-Line Treatment of PV
December 12th 2017Ruben A. Mesa, MD, Director of the UT Health San Antonio Cancer Center, discusses 4-year follow-up results from the phase III RESPONSE trial, which investigated ruxolitinib (Jafaki) with best available therapy for the treatment of polycythemia vera (PV) during the 2017 ASH Annual Meeting.
Watch
Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma
December 12th 2017Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.
Watch
Exploring Early Ibrutinib Intervention in High-Risk CLL
December 10th 2017Kerry Rogers, MD, Assistant Professor, Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses a phase II trial of early intervention with ibrutinib (Imbruvica) in patients with asymptomatic, high-risk chronic lymphocytic leukemia (CLL) during the 2017 ASH Annual Meeting.<br />
Watch
Using Checkpoint Blockade Inhibitors in Relapsed Hematologic Malignancies After Stem Cell Transplant
December 10th 2017Matthew S. Davids, MD, Associate Director, Dana-Farber Cancer Institute Center for Chronic Lymphocytic Leukemia, discusses a study that explored optimizing checkpoint blockade as a treatment for relapsed hematologic malignancies after allogenic hematopoietic cell transplantation during the 2017 ASH Annual Meeting.<br /> <br />
Watch
Enzalutamide Shows Promise in HR+ Breast Cancer
December 7th 2017Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.
Watch
Getting Genetic Testing to Those Who Need It
December 7th 2017Julie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.
Watch
The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer
December 7th 2017Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.
Watch
Venetoclax for the Treatment of Elderly Patients With CLL
December 7th 2017Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses venetoclax (Venclexta) for the treatment of elderly patients with chronic lymphocytic leukemia (CLL).
Watch
Optimal Treatment Sequencing for Patients With CLL
December 5th 2017Kanti R. Rai, MD, professor, The Karches Center for Oncology Research, The Feinstein Institute for Medical Research, director, Center for Oncology and Cell Biology, Long Island Jewish Medical Center, professor, Medicine and Molecular Medicine, Hofstra Northwell School of Medicine, discusses optimal treatment sequencing for patients with chronic lymphocytic leukemia (CLL).
Watch
Choosing Between TAS-102 and Regorafenib in Colorectal Cancer
November 30th 2017Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses choosing between TAS-102 (Lonsurf) and regorafenib (Stivarga) in colorectal cancer.
Watch
Decision Making in the Frontline Treatment of Metastatic Colon Cancer
November 29th 2017John L. Marshall, MD, Director, The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center, discusses decision making in the frontline treatment of patients with metastatic colon cancer.
Watch
Ovarian Suppression and Bone Management in Breast Cancer
November 29th 2017Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses ovarian suppression and bone cancer management in breast cancer.
Watch
Latest Advances in the Development of CDK4/6 Inhibitors in HR+ Breast Cancer
November 27th 2017Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses advances in the development of CDK4/6 inhibitors for the treatment of hormone receptor (HR)-positive breast cancer.
Watch
How the Treatment Paradigm for EGFR+ Lung Cancer Will Transform
November 27th 2017Justin F. Gainor, MD, medical oncologist, Assistant Professor of Medicine, Massachusetts General Hospital, Harvard Medical School, discusses how the treatment paradigm for EGFR+ lung cancer will transform over the next several years.
Watch
The Influence of the Gut Microbiome on Response to Anti-PD-1 Therapy in Melanoma
November 16th 2017Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.
Watch